Aclaris Therapeutics (ACRS) Short term Debt (2017 - 2022)
Aclaris Therapeutics' (ACRS) quarterly Short term Debt came in at $2.7 million in Q3 2022, down 12.2% year-on-year from $3.1 million in Q3 2021, and little changed quarter-over-quarter from $2.7 million in Q2 2022.
Aclaris Therapeutics (ACRS) Short term Debt (2017 - 2022) Analysis & Trends
Aclaris Therapeutics' Short term Debt history runs 3 years deep, the most recent figure standing at $2.7 million for Q3 2022.
- On a quarterly basis, Short term Debt fell 12.2% year-over-year to $2.7 million in Q3 2022; TTM through Sep 2022 was $2.7 million, a 12.2% decrease from a year earlier, with the FY2021 full-year figure at $2.6 million, changed N/A from the prior year.
- Short term Debt steadied at $2.7 million in Q3 2022 per ACRS's latest filing, from $2.7 million in the prior quarter.
- Across five years, Short term Debt topped out at $3.1 million in Q2 2021 and bottomed at $2.6 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Aclaris Therapeutics | 705.88 Mn | 705.88 Mn | 1.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 2.70 Mn |
| Jun 30, 2022 | 2.70 Mn |
| Mar 31, 2022 | 2.70 Mn |
| Dec 31, 2021 | 2.65 Mn |
| Sep 30, 2021 | 3.08 Mn |
| Jun 30, 2021 | 3.08 Mn |
| Dec 31, 2017 | 590,000.00 |